188Re-SSS lipiodol
90Y-loaded microspheres
hepatocellular carcinoma (HCC)
radiation therapy
radioembolization
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Apr 2023
11 Apr 2023
Historique:
received:
20
02
2023
revised:
03
04
2023
accepted:
05
04
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Despite the wide development of Lip-Re-01 was an activity-escalation Phase 1 study involving HCC patients progressing after sorafenib. The primary endpoint was safety based on Common Terminology Criteria for Adverse Events (AEs) of Grade ≥3 within 2 months. Secondary endpoints included bio-distribution assessed by scintigraphy quantification from 1 to 72 h, tumor to non-tumor uptake ratio (T/NT), as well as blood, urine and feces collection over 72 h, dosimetry, and response evaluation (mRECIST). Overall, 14 heavily pre-treated HCC patients were treated using a whole liver approach. The mean injected activity was 1.5 ± 0.4 GBq for activity Level 1 ( The high in vivo stability of
Sections du résumé
BACKGROUND
BACKGROUND
Despite the wide development of
METHOD
METHODS
Lip-Re-01 was an activity-escalation Phase 1 study involving HCC patients progressing after sorafenib. The primary endpoint was safety based on Common Terminology Criteria for Adverse Events (AEs) of Grade ≥3 within 2 months. Secondary endpoints included bio-distribution assessed by scintigraphy quantification from 1 to 72 h, tumor to non-tumor uptake ratio (T/NT), as well as blood, urine and feces collection over 72 h, dosimetry, and response evaluation (mRECIST).
RESULTS
RESULTS
Overall, 14 heavily pre-treated HCC patients were treated using a whole liver approach. The mean injected activity was 1.5 ± 0.4 GBq for activity Level 1 (
CONCLUSION
CONCLUSIONS
The high in vivo stability of
Identifiants
pubmed: 37190173
pii: cancers15082245
doi: 10.3390/cancers15082245
pmc: PMC10137154
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
J Hepatol. 2022 Apr;76(4):862-873
pubmed: 34902530
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
Nucl Med Commun. 2004 Oct;25(10):1007-13
pubmed: 15381868
World J Surg. 2013 Jun;37(6):1356-61
pubmed: 23463394
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699
pubmed: 35146577
Appl Radiat Isot. 2011 Feb;69(2):426-30
pubmed: 21106381
Nucl Med Biol. 1995 Apr;22(3):379-86
pubmed: 7627154
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Hepatology. 2021 Nov;74(5):2342-2352
pubmed: 33739462
J Nucl Med. 1994 Nov;35(11):1782-7
pubmed: 7525901
Lancet. 1999 Mar 6;353(9155):797-801
pubmed: 10459961
J Nucl Med. 2005 Jan;46(1):60-6
pubmed: 15632035
Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):344-52
pubmed: 16333675
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Semin Nucl Med. 2008 Mar;38(2):S40-5
pubmed: 18243842
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1506-1517
pubmed: 30715571
Ann Surg Oncol. 2014 Aug;21(8):2700-7
pubmed: 24743904
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Nucl Med Commun. 2004 Mar;25(3):291-7
pubmed: 15094449
Acta Radiol. 1989 Jul-Aug;30(4):419-25
pubmed: 2550044
Nucl Med Commun. 2004 Jul;25(7):691-9
pubmed: 15208496
Gastroenterology. 2010 Jan;138(1):52-64
pubmed: 19766639
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):163-71
pubmed: 20421150
Nucl Med Commun. 2021 Jan;42(1):43-50
pubmed: 32956248
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29
pubmed: 33166497